HIV-associated lipodystrophy

HIV-associated lipodystrophy (HALS) is a condition that affects individuals who are HIV-positive, and is characterized by a redistribution of fat in the body. This condition is often associated with antiretroviral therapy (ART), which is used to manage HIV infection.

Symptoms

The symptoms of HIV-associated lipodystrophy can vary widely among individuals. Some people may experience significant changes in their physical appearance, including:

• Lipoatrophy: This involves the loss of subcutaneous fat, particularly in the face, arms, and legs.
• Lipohypertrophy: This involves the accumulation of fat in areas such as the abdomen, breasts, and back of the neck.

Other symptoms can include insulin resistance, dyslipidemia, and an increased risk of cardiovascular disease.

Causes

The exact cause of HIV-associated lipodystrophy is not fully understood. However, it is believed to be related to the use of certain antiretroviral drugs, particularly those in the class of protease inhibitors and nucleoside reverse transcriptase inhibitors (NRTIs). Other factors, such as the duration of HIV infection and the individual's genetic makeup, may also play a role.

Treatment

Treatment for HIV-associated lipodystrophy can involve a combination of lifestyle changes, medication adjustments, and sometimes surgery. Lifestyle changes can include diet and exercise to manage weight and improve insulin sensitivity. In some cases, switching to a different antiretroviral drug can help to alleviate symptoms. Surgical options, such as liposuction or fat grafting, may be considered for individuals with severe lipoatrophy or lipohypertrophy.

See also

• HIV/AIDS
• Antiretroviral therapy
• Lipodystrophy
• Lipoatrophy
• Lipohypertrophy

References

HIV-associated lipodystrophy Resources
Latest articles Most recent articles Ongoing trials	Wikipedia